

**CHARACTERIZATION OF MUTANTS AND SPLICE  
VARIANTS OF HEPATITIS B VIRUS ISOLATED FROM  
SOUTH AFRICAN BLACK HEPATOCELLULAR  
CARCINOMA PATIENTS.**

Michelle Skelton

Thesis submitted in compliance for the requirements for the degree of  
Doctor of Philosophy in the Faculty of Health Sciences at the  
University of the Witwatersrand

Johannesburg 2009

**DECLARATION**

I, Michelle Skelton declare that this thesis is my own work. It is be being submitted for the degree of Doctor of Philosophy in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

.....

.....day of.....(month), 2009

**DEDICATION**

**I dedicate this thesis to my dear and late grandparents**

**Lydia Deist, Mary Skelton and Frederick Deist.**

## PRESENTATIONS

1. Conference: Cancer Research UK Beatson International Cancer Conference, pg 115, Scotland, UK.  
**Poster:** Michelle Skelton, Gerald C Kimbi, Anna Kramvis and Michael C. Kew (2005). Characterization of hepatitis B virus mutants in hepatocellular carcinoma in southern Africa.
2. Workshop: South African-Swedish Research Partnership (SIDA/NRF) Workshop Phylogenetic analysis of Hepatitis viruses found in Southern Africa relative to those from other geographic regions of the world. UWC, Cape Town, South Africa (2006).  
**Presentation:** Characterization of hepatitis B virus mutants in hepatocellular carcinoma in southern Africa.
3. MRC review of the Molecular Hepatology Research Unit in Johannesburg (27 June 2006).  
**Presentation:** Characterization of hepatitis B virus mutants in hepatocellular carcinoma in southern Africa.
4. Symposium: Hepatitis B Virus Genotypes ~ from an academic question to the clinic (July 2008).  
**Presentation:** Subgenotype A1 splice variants and mutants isolated from serum of South Africa hepatocellular carcinoma patients.

## ABSTRACT

Hepatitis B virus (HBV) infection is endemic in Africa. As many as 98% of black Africans are infected during their lives and about 10% (65 million) have chronic HBV infection, which is the cause of 70-80% of all hepatocellular carcinoma (HCC) cases. Despite this high prevalence of HBV and the high incidence of HCC in Africa, relatively few complete HBV genomes from African HCC cases have been deposited in international data bases. In order to gain a clearer understanding of the role of genetic variants and mutants in the development of HCC, the complete genomes of HBV isolated from southern African HCC patients were amplified and molecularly characterized. HBV DNA was extracted from the serum forty HBsAg-positive HCC patients. Twenty six complete genomes were successfully amplified, cloned and sequenced from nine HCC patients.

Phylogenetic analyses of the complete genomes and the individual open reading frames of HBV isolates from the HCC patients, led to the classification of all the isolates within subgenotype A1. No isolates belonging to subgenotype A2 and genotype D were identified, even though these genotypes/subgenotypes have been shown to circulate in South Africa. Three patients contained the uncommon combination of serological subtype *ayw1* in the subgenotype A1 strain. This combination has been found previously in South Africa and the Phillipines.

Seventy-eight percent of the patients carried HBV strains with the double basic core promoter (BCP) mutation (1762T/1764A), previously shown to reduce HBeAg expression. Furthermore, complete genome sequence analysis has revealed a complex combination of mutations, which include at least three or five of these residues 1753C1762T1764A1766T1768A1809T1812T occurring as the dominant

HBV strains isolated from 5/9 HCC patients. These mutations have previously been shown to regulate gene expression at various levels, to enhance viral replication and simultaneously decrease HBeAg expression.

All five HBV genomes isolated from one patient contained novel complex BCP rearrangements, which introduced 2 HNF1 and 1 putative HNF3 transcription factor binding sites. These mutations can enhance viral replication and simultaneously abolish HBeAg expression at a transcriptional level. Furthermore, truncated core proteins would be expressed from 4/5 isolates and none would express wild-type HBx. Several mutations were identified in the pre-S/S genes of 2/5 isolates, which would result in the expression of novel 3' truncated medium surface proteins (MHBs<sup>t</sup>) and large surface proteins (LHBs<sup>t</sup>). The majority of the mutations would contribute to hepatocyte pathogenesis and transformation by activating cell proliferating pathways.

Two patients also contained rare HBV variants not previously identified in HBV strains from southern Africa. These included an HBV splice variant and a poly (dA) variant from patient 10 and patient 6, respectively. These variants occurred in combination with other isolates within the respective patients.

The envelope genes were characterised in a total of 18 HCC patients, the pre-S gene of HBV contained deletions in 72% of the patients. Deletions across pre-S1/pre-S2, pre-S2 initiation codon mutations with internal deletions, and S gene nonsense mutations were prevalent. Mutated envelope proteins have been shown to accumulate within the hepatocyte endoplasmic reticulum (ER) and are a characteristic histopathological hallmark of HCC known as ground glass

hepatocytes. HBV induced ER stress has been shown to dysregulate several cell cycle regulatory pathways, which contribute to HCC.

In addition several novel LHBs<sup>†</sup> and MHBs<sup>†</sup> have been described. These potential transactivators require further investigation. The HBV mutations described in this study have been associated with increased risk for HCC.

Despite the obvious heterogeneity HBV displays within and between patients, there are common characteristics shared between the HBV variants which emerge during the development of HCC. These include the BCP and pre-C (1753C1762T1764A1766T1768A1809T1812T) mutations and the pre-S/S mutations. These mutations are able to affect HBV replication and gene expression, and may work synergistically to promote liver dysfunction and HCC.

**ACKNOWLEDGEMENTS**

Firstly, I would like to thank my supervisor, Professor Michael Kew. His enthusiasm towards my project has been a source of encouragement. He has taken much time and care in editing my thesis. He has provided invaluable criticism through his combined experience and expertise in clinical and molecular hepatitis research. It is an honour to be associated with such an accomplished leader in the field of hepatitis and cancer research.

I would also like to thank my co-supervisor, Professor Anna Kramvis, affectionately known as, Anna. This project was her brainchild. Anna is a visionary in the field of molecular evolution of HBV and I am proud to be her student. Thank you for your idealism and pursuit for excellence. You have encouraged me to thrash out every aspect of this thesis and I appreciate that.

I would like to thank the staff and friends in the Molecular Hepatology Research Unit at the University of the Witwatersrand. A special thanks to Roshni Desai for always being pleasant and carrying out her responsibilities timeously so that projects could run smoothly. Alice Chen, my dear friend thank you for your support. To Gerald Kimbi whose work laid the foundation for my research.

A warm thank you to my friends and colleagues at the University of Cape Town where I spent a considerable time writing and analysing data. Thank you for embracing me and helping me through a difficult time. A special thanks to Professor Iqbal Parker, Dr Sharon Prince, Widaad Zemanay, Catherine Whibley, Dr Virna Leaner and Gama Bandawe.



A huge thanks to my Dad for his love, patience, financial support and just being there. Mom, you appear to be the number one fan of this huge endeavour called my PhD. Thank you for all the faith you have in me, it has truly made all the difference. Thank you both for caring so much for me.

Thank you to all my family and friends who have always believed in me, it is much appreciated.

I would like to thank the National Research Foundation and the Poliomyelitis Research Foundation for their financial support.

## TABLE OF CONTENTS

### CHAPTER 1

<b>1.0</b>	<b>INTRODUCTION</b> .....	<b>1</b>
1.1	THE FAMILY OF <i>HEPADNAVIRIDAE</i> .....	4
1.2	VIRAL STRUCTURE .....	4
1.3	VIRAL GENOME .....	6
1.4	HBV TRANSCRIPTS .....	8
1.5	VIRAL GENE PRODUCTS .....	9
1.5.1	SURFACE PROTEINS .....	9
1.5.2	CORE GENE PRODUCTS .....	15
1.5.3	POLYMERASE .....	16
1.5.4	HBx PROTEIN .....	17
1.6	VIRAL <i>CIS</i> -ELEMENT .....	17
1.6.1	PROMOTERS AND ENHANCERS .....	17
1.6.2	THE ENCAPSIDATION SIGNAL .....	22
1.6.3	THE POLYADENYLATION SIGNAL .....	22
1.7	HBV LIFE CYCLE .....	23
1.8	IMMUNO-PATHOGENESIS OF HBV INFECTION .....	28
1.8.1	TRANSMISSION .....	28
1.8.2	PATHOGENESIS OF HBV INFECTION .....	28
1.8.3	ACUTE HEPATITIS .....	29
1.8.4	CHRONIC (PERSISTENT) HEPATITIS .....	30
1.8.5	HEPATOCELLULAR CARCINOMA .....	32
1.9	HBV GENOTYPES: MOLECULAR CHARACTERISTICS AND GLOBAL DISTRIBUTION .....	33
1.9.1	GENOTYPE A .....	37
1.9.2	GENOTYPE B .....	37
1.9.3	GENOTYPE C .....	38
1.9.4	GENOTYPE D .....	38
1.9.5	GENOTYPE E .....	38
1.9.6	GENOTYPE F .....	39
1.9.7	GENOTYPE G .....	39
1.9.8	GENOTYPE H .....	40
1.10	HBV SEQUENCE VARIATION .....	40
1.10.1	HBV GENOTYPES AND DISEASE PROGRESSION .....	41
1.10.2	HBV MUTANTS AND DISEASE PROGRESSION .....	43
1.10.2.1	CORE PROMOTER AND ENHANCER II REGION .....	43

1.10.2.2	PRECORE AND CORE GENE .....	45
1.10.2.3	X GENE.....	46
1.10.2.4	POLYMERASE REGION.....	48
1.10.2.5	THE PRE-S AND SURFACE REGION.....	49
1.11	PRE-S FAMILY OF TRANSACTIVATORS .....	53
1.12.	SPLICE VARIANTS AND VARIANTS WITH INTERNAL POLY (dA) TAILS.....	54
1.13	HBV DNA INTEGRATION .....	55
1.14	THE HB <sub>x</sub> TRANSACTIVATOR .....	55
1.15	RECOMBINANTS.....	56
1.16	HBV SEQUENCE VARIATION IN SOUTHERN AFRICA.....	57
1.17	AIMS AND ORGANIZATION OF STUDY .....	60

## CHAPTER 2

<b>2.0.</b>	<b>MATERIALS AND METHODS .....</b>	<b>63</b>
2.1	SUBJECTS AND SERUM SAMPLES.....	63
2.2	DNA EXTRACTION, AMPLIFICATION, CLONING AND SEQUENCING.....	65
2.2.1	DNA EXTRACTION.....	65
2.2.2	DNA AMPLIFICATION .....	65
2.2.2.1	COMPLETE GENOME AMPLIFICATION.....	65
2.2.2.2	SUB-GENOMIC AMPLIFICATION.....	66
2.2.2.3	SEMI-NESTED POLYMERASE CHAIN REACTION (PCR) .....	66
2.2.3	DETECTION OF AMPLICONS .....	69
2.2.4	CLONING OF AMPLICONS .....	69
2.3	DNA SEQUENCING .....	72
2.3.1	MANUAL SEQUENCING.....	72
2.3.1.1	PREPARATION OF PCR TEMPLATES .....	72
2.3.1.2	PREPARATION OF PLASMID DNA.....	72
2.3.1.3	PRIMER ANNEALING AND LABELLING REACTION.....	72
2.3.2	AUTOMATED SEQUENCING .....	73
2.4	PHYLOGENETIC ANALYSES.....	75
2.5	CONSTRUCTION OF SURFACE GENE EXPRESSION VECTORS .....	75
2.6	PREPARATION OF THE PRE-S/S GENE FRAGMENTS.....	76
2.7	LIGATION REACTION .....	77
2.8	SUB-CLONING STRATEGY .....	77

2.9	CELL CULTURE .....	79
2.9.1	CELL LINE .....	79
2.9.2	SUBCULTURE AND STOCKS .....	79
2.9.3	MYCOPLASMA TEST .....	80
2.10	CALCIUM PHOSPHATE TRANSFECTION .....	81
2.11	DETECTION OF B-GALACTOSIDASE .....	82
2.12	DOXORUBICIN TREATMENT .....	82
2.13	PROTEIN PURIFICATION .....	83
2.13.1	CELL LYSATE PREPARATION .....	83
2.13.2	PROTEIN QUANTITATION.....	83
2.14	WESTERN BLOT ANALYSIS.....	84
2.14.1	SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE).....	84
2.14.2	TRANSFER.....	84
2.14.3	PONCEAU S (MEMBRANE) AND COOMASSIE BLUE (GEL) STAINS.....	84
2.14.4	PRIMARY ANTIBODY.....	85
2.14.5	SECONDARY ANTIBODY.....	85
2.14.6	MEMBRANE STRIPPING.....	86
2.15	CASPASE 3 ASSAY.....	86
2.16	PLASMID DNA EXTRACTIONS FROM BACTERIAL CELLS.....	87
2.17	PREPARATION OF COMPETENT BACTERIAL CELLS.....	88
<b>CHAPTER 3</b>		
<b>3.0</b>	<b>RESULTS .....</b>	<b>89</b>
<b>3.1</b>	<b>SEQUENCE CHARACTERISTICS AND PHYLOGENETIC ANALYSIS OF HBV FROM BLACK SOUTHERN AFRICAN HEPATOCELLULAR CARCINOMA PATIENTS .....</b>	<b>89</b>
3.1.1	AMPLIFICATION, CLONING AND SEQUENCING.....	89
3.1.2	PHYLOGENETIC ANALYSIS .....	91
3.1.3	COMPARISON OF AMINO ACID SEQUENCES OF SUBGENOTYPE A1 HBV ISOLATES FROM HCC PATIENTS WITH THOSE FROM ASYMPTOMATIC, CHRONIC CARRIERS, ACUTE HEPATITIS PATIENTS AND FULMINANT HEPATITIS PATIENTS.....	100
3.1.4	COMPARISON OF NUCLEOTIDE SEQUENCES OF SUBGENOTYPE A1 HBV ISOLATED FROM HCC PATIENTS WITH ISOLATES FROM ASYMPTOMATIC CHRONIC CARRIERS, ACUTE AND FULMINANT HEPATITIS PATIENTS BELONGING TO SUBGENOTYPE A1.....	105

<b>3.2</b>	<b>SIMULTANEOUS ALTERATIONS IN THE BASIC CORE PROMOTER, CORE GENE AND SURFACE GENE</b> .....	108
3.2.1	PCR AND CLONING .....	108
3.2.2	FULL GENOME STRUCTURE .....	111
3.2.3	STRUCTURE OF THE BCP MUTATION.....	111
3.2.3.1	DELETION, INSERTION AND DUPLICATION .....	111
3.2.3.2	INITIATION SITES AND TA-RICH MOTIFS .....	112
3.2.3.3	TRANSCRIPTION FACTOR BINDING SITES.....	112
3.2.4	X-GENE MUTATIONS AND PREDICTED PROTEIN EXPRESSION .....	113
3.2.5	CORE GENE MUTATIONS AND PREDICTED PROTEIN EXPRESSION .....	113
3.2.6	SURFACE GENE MUTATIONS .....	114
<b>3.3</b>	<b>IDENTIFICATION AND MOLECULAR CHARACTERIZATION OF RARE HBV VARIANTS IN HEPATOCELLULAR CARCINOMA</b> .....	126
3.3.1	HBV ISOLATED FROM PATIENT 6 .....	128
3.3.1.1	GENOME HETEROGENEITY .....	131
3.3.1.2	STRUCTURE OF TYPE I GENOME.....	131
3.3.1.3	PREDICTED PROTEIN SEQUENCE .....	132
3.3.2	HBV ISOLATED FROM PATIENT 10 .....	133
3.3.2.1	GENOME HETEROGENEITY .....	136
3.3.2.2	STRUCTURE OF THE TYPE I GENOME.....	136
3.3.2.3	PREDICTED PROTEIN SEQUENCE .....	137
3.3.3	PHYLOGENETIC ANALYSIS .....	138
<b>3.4</b>	<b>CHARACTERISATION OF PRE-S MUTATIONS IN HBV ISOLATED FROM HCC PATIENTS</b> .....	140
3.4.1	PRE-S MUTATIONS .....	140
3.4.2	PRE-S MUTATION PATTERN AND HETEROGENEITY.....	141
3.4.3	C-TERMINALLY (3') TRUNCATED PRE-S/S GENE MUTANTS .....	143
3.4.4	PHYLOGENETIC ANALYSIS .....	142
<b>3.5</b>	<b>FUNCTIONAL ANALYSIS OF MUTANT PRE-S/S GENES</b> .....	152
<b>CHAPTER 4</b>		
<b>4.0</b>	<b>DISCUSSION</b> .....	157
<b>4.1</b>	<b>SEQUENCE CHARACTERISTICS AND PHYLOGENETIC ANALYSIS OF HBV FROM BLACK SOUTHERN AFRICAN HEPATOCELLULAR CARCINOMA PATIENTS</b> .....	157

4.1.1	HBV HETEROGENEITY.....	157
4.1.2	GENETIC RELATEDNESS AND PREDICTIVE MARKERS FOR HCC .....	158
4.1.3	SUBGENOTYPE A1 CHARACTERISTICS AND SIGNATURE SEQUENCES .....	165
4.1.4	MUTATIONS IN HBV PRE-C GENE AND BCP IN HCC IN SOUTHERN AFRICA .....	168
4.1.5	CONCLUSION .....	173
<b>4.2</b>	<b>SIMULTANEOUS ALTERATIONS IN THE BASIC CORE PROMOTER, CORE GENE AND SURFACE GENE.....</b>	<b>174</b>
4.2.1	HBV HETEROGENEITY WITHIN PATIENT 18 .....	174
4.2.2	PREVALENCE OF THE COMPLEX BCP MUTATIONS .....	175
4.2.3	HOMOLOGOUS RECOMBINATION MEDIATED BY TOPOISOMERASE I .....	178
4.2.4	BCP REARRANGEMENTS.....	184
4.2.5	THE CORE GENE AND PRODUCTS.....	187
4.2.6	THE PRE-S/S GENE AND PRODUCTS.....	188
4.2.7	THE X-GENE AND PRODUCTS .....	189
4.2.8	CUMULATIVE EFFECT OF MULTIPLE MUTATIONS IN ALL THE ORFS.....	190
4.2.9	CONCLUSION .....	191
<b>4.3</b>	<b>IDENTIFICATION OF RARE HBV VARIANTS IN HCC .....</b>	<b>192</b>
4.3.1.	HBV HETEROGENEITY IN PATIENT 6 AND PATIENT 10 .....	192
4.3.2.	THE POLY (dA) VARIANT.....	193
4.3.2.1	GENOME STRUCTURE AND REPLICATION STRATEGY.....	193
4.3.2.2	RECOMBINANT PROTEINS.....	194
4.3.3	HBV SPLICE VARIANT.....	196
4.3.3.1	GENOME STRUCTURE.....	196
4.3.3.2	RECOMBINANT PROTEINS.....	197
4.3.3.3	HBV SPLICE VARIANTS AND HCC.....	199
4.3.4	CONCLUSION .....	199
<b>4.4</b>	<b>CHARACTERISATION OF PRE-S/S GENE MUTANTS IN HCC IN BLACK SOUTHERN AFRICANS .....</b>	<b>201</b>
4.4.1	PREVALENCE AND DISEASE.....	201
4.4.2	THE PRE-S1 AND PRE-S2 REGIONS.....	202
4.4.3	PRE-S1/S2 MUTANTS AND GGHS .....	205

4.4.4	NOVEL TRANSACTIVATORS.....	205	
4.4.5	CELL CYCLE REGULATORY PATHWAYS AFFECTED BY $\Delta$ PRE-SLHBS/MHBS.....	208	
4.4.6	CONCLUSION .....	209	
<b>4.5</b>	<b>MUTANT PRE-S/S GENES AND THE CELL CYCLE REGULATORY PATHWAYS .....</b>	<b>210</b>	
4.5.1	CONCLUSION .....	215	
<b>CHAPTER 5</b>			
<b>5.0</b>	<b>GENERAL CONCLUSION .....</b>	<b>216</b>	
<b>APPENDICES .....</b>			<b>220</b>
<b>APPENDIX A: SOLUTIONS AND REAGENTS.....</b>			<b>220</b>
<b>APPENDIX B: Figure B1 .....</b>			<b>225</b>
<b>REFERENCES .....</b>			<b>233</b>

**LIST OF FIGURES**

Figure 1.1	Geographical distribution of chronic hepatitis B virus Infection.....	3
Figure 1.2A	Diagrammatic representation of a Dane particle or complete HBV virion. The envelope is made up of LHBs, MHBs and SHBs .....	5
Figure 1.2B	Filamentous sub-viral particle, which are mainly made up of SHBs and MHBs.....	5
Figure 1.2C	Spherical viral particle is composed mainly of SHBs and MHBs.....	5
Figure 1.3	Organization of the HBV genome.....	7
Figure 1.4	A schematic representation of the HBV surface proteins. ....	12
Figure 1.5	Transmembrane topology of the HBV envelope proteins. ....	14
Figure 1.6	Core promoter/Enhancer II region .....	21
Figure 1.7A	The HBV life cycle. ....	25
Figure 1.7B	Representation of viral replication.....	26
Figure 1.8	Outline of HBV-induced disease and the prevalences of the various sequelae characteristic of southern Africans .....	29
Figure 1.10	The 'a' determinant of the HBsAg occurring within the major hydrophilic loop.....	52
Figure 2.1	Flow diagram of methodology .....	64
Figure 3.1	Dendrogram based on the complete genomes of 24 genotype A1 isolates from HCC and representative sequences from subgenotype A1, A2 and the 7 remaining genotypes .....	94
Figure 3.2	Dendrogram based on the complete polymerase genes of 24 subgenotype A1 isolates from HCC and representative sequences from subgenotype A1, A2 and the 7 remaining genotypes.....	95
Figure 3.3	Dendrogram based on the complete pre-C/Core genes of 24 subgenotype A1 isolates from HCC and representative sequences from subgenotype A1, A2 and the 7 remaining genotypes.....	96
Figure 3.4	Dendrogram based on the complete surface genes of 24 subgenotype A1 isolates from HCC and representative sequences from subgenotype A1, A2 and the 7 remaining genotypes .....	97
Figure 3.5	Dendrogram based on the complete X-genes of 24	



	subgenotype genotype A1 isolates from HCC and representative sequences from subgenotype A1, A2 and the 7 remaining genotypes .....	98
Figure 3.6	Comparison of amino acid residues of S, polymerase and X-ORFs of subgenotype A1 isolates from HCC patients, asymptomatic chronic carriers, acute hepatitis patients and fulminant hepatitis patients.....	101
Figure 3.7	Comparison of nucleic acid sequences of the <i>cis</i> -acting elements of subgenotype A1 isolates from HCCs, asymptomatic chronic carriers and acute hepatitis patients. Dots indicate amino acid identity.....	103
Figure 3.8	PCR amplicons and plasmid DNA restriction digest of HBV clones derived from patient 18 .....	109
Figure 3.9	Full-genome structure of five HCC 18 clones with genome lengths determined by complete sequence analysis .....	110
Figure 3.10	Nucleotide sequence of the BCP (nt 1741-nt 1849) genotype A .....	115
Figure 3.10.A	Initiation sites of the precore (pre-C) mRNA and pregenomic (pg) RNA are shown as horizontal arrows and initiators (Inr) are shown in italics. The BCP contains four AT-rich domains (TA1-TA4).The positions of the 13 nucleotide deletion and the 45 nucleotide insertion are indicated.....	115
Figure 3.10.B	Reorganization of the AT-rich domains in BCP for all five clones. TA2 motifs are shown in bold and a new motif TATTA and TTAAATATTA are underlined .....	115
Figure 3.10.C	Two 27 nucleotide repeats are underlined and are made up of a recombination of overlapping adjacent sequences, demonstrated by the overlapping triangles .....	115
Figure 3.11	Nucleotide sequence of the Core promoter showing transcription factor binding sites.....	117
Figure 3.12	Predicted X protein amino acid sequences expressed from mutants.....	119
Figure 3.13	Structure of the core gene mutation.....	120
Figure 3.14	Chromatogram produced following automated sequencing of the core gene of HBV isolated from patient 18.....	122
Figure 3.15	HBV full-length PCR amplicons from patient DNA resolved on 1% agarose gels stained with ethidium bromide.....	127
Figure 3.16	<i>PvuII</i> restriction digestion products of cloned HBV resolved on a 1%	

	agarose gel.....	128
Figure 3.17	Full-genome structure of 6 clones derived from HCC patient 18 determined using sequence analysis.....	129
Figure 3.17.A	At the top is a schematic presentation of the genome structure with four overlapping reading frames and the relevant <i>cis</i> -elements, including the basic core promoter (BCP), direct repeat 1 (DR1), direct repeat 2 (DR 2), polyadenylation signal (poly A). The poly (dA) tail is shown in the rectangular box, followed by a large deletion illustrated with the broken line and dots .....	129
Figure 3.17.B	Chromatograph of clone 6.1 HBV DNA sequence obtained using primer T3.....	129
Figure 3.18	Amino acid sequence of the recombinant protein generated for the core-polymerase ORF of the poly (dA) variant. ....	132
Figure 3.19	Molecular structure of three HBV genomes isolated from HCC patient 10 determined by complete sequence analysis. ....	134
Figure 3.19.A	At the top is a schematic presentation of the genome structure with four overlapping reading frames and the relevant <i>cis</i> -elements. The basic core promoter (BCP), direct repeat 1 (DR1) and direct repeat 2 (DR 2). The large deletion is illustrated with the broken line and dots. ....	134
Figure 3.19B	Deletion boundary sequences of genome 10.17 were aligned to the consensus sequences for the 5' – splice site (MAG/GTRAGT), the 3' splice site (YAG/G), and the branch site (YNYRAY) (Jackson, 1991).The branch site and polypyrimidine tract are indicated, non-negotiable nucleotides are shown in bold .....	134
Figure 3.20	Amino acid sequence of the recombinant protein generated for the core-polymerase ORF of the splice variant. ....	137
Figure 3.21	Dendrogram based on the complete X-genes of 26 subgenotype genotype A1 isolates from HCC and representative sequences from subgenotype A1, A2 and the 7 remaining genotypes.....	139
Figure 3.22.A	Amino acid sequence alignment of the preS1 region .....	144
Figure 3.22.B	Amino acid sequence alignment of the preS1 region. ....	145
Figure 3.23	Schematic presentation of pre-S mutation patterns found in the southern African HBV subgenotype A1 isolates. ....	149

Figure 3.24	Schematic presentation of LHB, LHB 3' truncated mutants (LHBs <sup>t</sup> ) and MHB 3' truncated mutants (MHBs <sup>t</sup> ). .....	150
Figure 3.25	Dendrogram based on the complete surface genes of 47 subgenotype genotype A1 isolates from HCC and representative sequences from subgenotype A1, A2 and the 7 remaining genotypes.....	151
Figure 3.26	Schematic presentation of the preS/S gene constructs (pre-S variants).....	154
Figure 3.27A	Transfection efficiency measure in parallel using X-gal staining .....	155
Figure 3.27B	p21 <sup>Waf-1</sup> western blot analysis.....	155
Figure 3.27C	Caspase 3 activity.....	155
Figure 4.1.	Proposed model of Topoisomerase I-mediated recombination in the HBV strains isolated from patient 18.....	180

**LIST OF TABLES**

Table 1.1.	HBV Transcripts.....	8
Table 1.2.	Genotype Variations .....	34
Table 1.3.	Geographical Distribution of Genotypes and Subgenotypes .....	36
Table 2.1.	PCR Primers and conditions used for amplification.....	67
Table 2.2.	Primers used for sequencing .....	74
Table 2.3.	Ligation Reaction Components.....	77
Table 2.4.	Surface gene expression vectors.....	79
Table 2.5.	Calcium Phosphate transfection components .....	81
Table 2.6.	Antibodies used in the Western Blot Analysis .....	86
Table 3.1.1.	PCR and Cloning HBV Data of HCC Patients.....	90
Table 3.1.2.	Mean pair-wise DNA divergence (%) of complete genome sequences and individual ORFs of subgenotype A1 in different patient groups .....	93
Table 3.1.3.	Mutations within the <i>cis</i> -acting regulatory elements found in subgenotype A1 HCC patients.....	106
Table 3.1.4.	Core promoter and precore mutations occurring in complete genomes of HCC patients in the current study.....	107
Table 3.2.1.	Mutations in the cloned HBV genomes detected by sequence analysis .....	124
Table 3.4.1.	Deletions in the pre-S domain and nucleotide position.....	147
Table 3.4.2.	Mutations within the Virion Morphogenesis Domain (aa 103-124)	148

**LIST OF ABBREVIATIONS**

$\epsilon$	encapsidation signal
aa	amino acid
ALT	Alanine aminotransferase
APC	Antigen presenting cell
ASC	Asymptomatic chronic carrier
AS	Asymptomatic chronic carrier (pertaining to figures)
ASHV	Arctic squirrel hepatitis B virus
bp	base pair
BCP	Basic core promoter
BQW	Best quality water
cccDNA	Covalently closed circular DNA
COR	Cohesive overlap region
COUP-TF	Chicken ovalbumin upstream promoter transcription factor
CURS	Core upstream regulatory sequence
DHBV	Duck hepatitis B virus
DNA	Deoxyribonucleic Acid
DNAML	DNA maximum likelihood
DR1	Direct repeat one
DR2	Direct repeat two
ERK	Extracellular signal-regulated kinase
ENHI	Enhancer one
ENHII	Enhancer two
ER	Endoplasmic reticulum
ESLD	End stage liver disease

GGH	Ground glass hepatocyte
GHSV	Ground squirrel hepatitis B virus
HBcAg	Hepatitis B core antigen
HBeAg	Hepatitis B e antigen
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HHBV	Heron hepatitis B virus
HNF	Hepatocyte nuclear factor
IFN	Interferon
IPTG	isopropyl-beta-D-thiogalactopyranoside
kb	kilobase
LB	Luria-Bertini broth
LHBs	Large surface proteins
LHBs <sup>t</sup>	Truncated large surface proteins
MAPK	Mitogen activated protein kinase
MHBs	Medium surface proteins
MHBs <sup>t</sup>	Truncated medium surface proteins
mRNA	messenger RNA
Myr	Myristoylation
NEIGHBOR	neighbour-joining
NG	N-glycosylation
NRE	Negative regulatory element
OG	O-glycosylation
ORF	Open reading frame

PCR	Polymerase chain reaction
PK	Protein kinase
PKC	Protein kinase C
Pol	polymerase
Poly A	polyadenylation signal
PPAR $\alpha$	peroxisome proliferator activated receptor $\alpha$
PHYLIP	phylogeny inference package
RT	reverse transcriptase
RXR $\alpha$	retinoid X receptor $\alpha$
SHBs	Small (major) surface proteins
TBP	TATA binding protein
TP	terminal protein
Top I	Topoisomerase I
TR2	Human testicular receptor 2
URR	Upstream regulatory element
UV	Ultraviolet
WHO	World Health Organization
WHV	Woodchuck hepatitis B virus
WMHBV	Woolly Monkey hepatitis B virus
YMDD	Tyrosine, Methionine, Aspartic acid, Aspartic acid
YIDD	Tyrosine, Isoleucine, Aspartic acid, Aspartic acid
YVDD	Tyrosine, Valine, Aspartic acid, Aspartic acid